Jake Chabon

Jake Chabon (Ph.D.) is the CEO & CSO of Foresight Diagnostics, which he co-founded with academic partners in 2020. He is a molecular biologist and bioinformatic scientist with more than 20 peer-reviewed publications and 2,700+ citations to date (including a Nature paper related to Foresight’s liquid biopsy platform).

Prior to founding Foresight, Dr. Chabon’s research focused on using cancer genomics to inform more personalized treatment strategies for cancer patients. He has extensive experience with NGS assay development with an emphasis on developing non-invasive cancer detection methods and applying these methods to better understanding mechanisms of response and resistance to cancer therapies.

Jake completed his Ph.D. and his postdoctoral training at Stanford University under the co-mentorship of Dr. Max Diehn and Dr. Ash Alizadeh with whom he co-founded Foresight Diagnostics.